A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Phase of Trial: Phase III
Latest Information Update: 17 May 2018
At a glance
- Drugs Pamiparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 17 May 2018 According to the BeiGene media release, this trial is designed to provide important confirmatory clinical data that could enable registration in the maintenance setting, as well support our planned initial regulatory submission for the treatment of patients with advanced ovarian cancer who carry a germline BRCA1/2 mutation.
- 17 May 2018 According to the BeiGene media release, first patient was enrolled in this study.
- 11 Mar 2018 Status changed from not yet recruiting to recruiting.